Aspirin can stimulate luminol-enhanced chemiluminescence of activated platelets

Abstract

A preliminary investigation was conducted into the influence of aspirin on the luminol-enhanced chemiluminescence of platelets stimulated with platelet-activating factor (PAF). Ten coronary artery disease patients and six volunteers without coronary artery disease were included in the study. All the patients received aspirin (daily dose, 100 mg) for at least 10 days before in vitro experiments. Luminol-enhanced luminescence of platelet-rich plasma samples mixed with a PAF solution was measured. After stimulation of platelets with PAF, we did not find a luminol-enhanced chemiluminescent response either in the non-coronary artery disease volunteers or in eight out of the 10 coronary artery disease patients examined. However, in samples from two patients where platelets were stimulated with PAF reactive oxygen species were formed. This ability was expressed as an intensive luminol-enhanced luminescence of activated platelets. Such a reaction was observed against the background of the administration of aspirin. The addition of aspirin to a test tube considerably enhanced the intensity of chemiluminescence. In one case, the cancellation of aspirin was accompanied by diminution of the intensity of luminol-enhanced chemiluminescence of platelets. The clinical significance of this phenomenon is unknown.

Activated platelet chemiluminescence and presence of CD45+ platelets in patients with acute myocardial infarction

“…In our previous study 2 out of 10 CAD patients demonstrated similar ROS generation in response to stimulation with PAF. In the study it has been shown that aspirin can stimulate ROS generation in vitro, and the intake of aspirin by the studied CAD patients was suggested as a possible explanation of observed generation of ROS in two of them [8]. In the current study, patients were also receiving aspirin and its intake can be the reason of increased ROS production 8-10 days after AMI onset.…”

“…Platelets in some coronary artery disease (CAD) patients are potent ROS producers [8]. However, mere activation of isolated platelets seems not to be enough for ROS generation, since even potent inducers of platelet aggregation such as phorbol ester, calcium ionophore A23187, and thrombin, while causing platelet aggregation do not trigger ROS production, as evaluated from low chemiluminescence in the presence of luminol [9].…”

Platelet chemiluminescence and endothelial dysfunction in patients with acute myocardial infarction

“…УЛХТ измеряли в относительных световых единицах (relative light unit -RLU). Более подробное описание этапов проведения измерения ФАТ-стимулированной УЛХТ опубликовано нами ранее [10,11].…”

“…Усиленная люминолом хемилюминесценция позволяет оценить образование АФК в тромбоцитах. Вырабатываемые АФК могут выполнять роль вторичных мессенджеров и регулировать функцию тромбоцитов [9,10]. В наших предыдущих работах была продемонстрирована in vitro возможность усиленной люминолом хемилюминесценции тромбоцитов (УЛХТ), Results.…”

“…стимулированной фактором, активирующим тромбоциты (ФАТ) [10,11]. Учитывая, что увеличение продукции АФК и снижение уровня NO являются одними из главных молекулярных механизмов, приводящих к развитию эндотелиальной дисфункции, целью нашего исследования было оценить эндотелиальную функцию в зависимости от уровня усиленной люминолом хемилюминесценции тромбоцитов, стимулированной фактором, активирующим тромбоциты, у пациентов с острым инфарктом миокарда (ОИМ) и у здоровых добровольцев.…”